Ruiling Zu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruiling Zu has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Huaichao Luo
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
22 shared publications - Dongsheng Wang
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
20 shared publications - Jian Huang
School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China
19 shared publications - Lubei Rao
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
19 shared publications - Peiying Zhang
Innovative Institute of Chinese Medicine and Pharmacy, Academy for Interdiscipline, College of Medical Technology, Chengdu University of Traditional Chinese Medicine , Chengdu 611137
18 shared publications - Xing Yin
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
18 shared publications
Latest Publications
- Open Access
- 20 December 2025
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 42 (1)
Tumor-mediated remote regulation of peripheral blood platelets
The role of platelets in blood coagulation and vascular repair is well known. In recent years, extensive attention has been given to the fact that the impact of tumors on peripheral blood platelets plays a key role in cancer progression. This review systematically summarizes the latest research progress on how tumors regulate the quantity, volume, composition, and activation status of peripheral blood platelets through multiple mechanisms. First, tumor cells can induce excessive platelet production by activating AhR-RUNX1 signaling through paracrine pathways and the release of kynurenine, thereby leading to thrombocytosis, which is associated with advanced tumor stages, metastasis, and poor prognosis. Second, tumor progression may trigger disseminated intravascular coagulation (DIC) or chemotherapy-related bone marrow suppression, which in turn results in consumptive thrombocytopenia. In addition, dynamic changes in the mean platelet volume (MPV) are related to tumor type and progression stage, which may reflect abnormal megakaryocyte differentiation or inflammatory status. In terms of platelet composition, tumor cells can remodel the proteome and transcriptome of platelets by secreting ADP, IgG, and functional RNA. Changes in RNA profiles have been confirmed to have potential for tumor diagnosis. In terms of activation status, tumor cells can induce platelet activation and aggregation (TCIPA) by releasing procoagulant factors such as tissue factors and exosomes (EVs), accelerating thrombosis and promoting angiogenesis. In clinical applications, platelet-related biomarkers have become a research hotspot for early cancer diagnosis and prognostic evaluation. Moreover, targeting platelets affected by tumors provides new strategies for tumor treatment. On the basis of the scientific findings of numerous existing studies, it is speculated that there seems to be a "dynamic balance" among platelets, which also provides a new direction for future research.
- 20 December 2025
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 42 (1)
Open AccessTumor-mediated remote regulation of peripheral blood platelets
The role of platelets in blood coagulation and vascular repair is well known. In recent years, extensive attention has been given to the fact that the impact of tumors on peripheral blood platelets plays a key role in cancer progression. This review systematically summarizes the latest research progress on how tumors regulate the quantity, volume, composition, and activation status of peripheral blood platelets through multiple mechanisms. First, tumor cells can induce excessive platelet production by activating AhR-RUNX1 signaling through paracrine pathways and the release of kynurenine, thereby leading to thrombocytosis, which is associated with advanced tumor stages, metastasis, and poor prognosis. Second, tumor progression may trigger disseminated intravascular coagulation (DIC) or chemotherapy-related bone marrow suppression, which in turn results in consumptive thrombocytopenia. In addition, dynamic changes in the mean platelet volume (MPV) are related to tumor type and progression stage, which may reflect abnormal megakaryocyte differentiation or inflammatory status. In terms of platelet composition, tumor cells can remodel the proteome and transcriptome of platelets by secreting ADP, IgG, and functional RNA. Changes in RNA profiles have been confirmed to have potential for tumor diagnosis. In terms of activation status, tumor cells can induce platelet activation and aggregation (TCIPA) by releasing procoagulant factors such as tissue factors and exosomes (EVs), accelerating thrombosis and promoting angiogenesis. In clinical applications, platelet-related biomarkers have become a research hotspot for early cancer diagnosis and prognostic evaluation. Moreover, targeting platelets affected by tumors provides new strategies for tumor treatment. On the basis of the scientific findings of numerous existing studies, it is speculated that there seems to be a "dynamic balance" among platelets, which also provides a new direction for future research.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Evaluation of confounding factors and the analysis of clinical applicability for the TCRnodseek plus model
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Evaluation of confounding factors and the analysis of clinical applicability for the TCRnodseek plus model
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Indeterminate pulmonary nodules (IPN) are increasingly detected due to increasing health awareness and widespread lung cancer screening, yet distinguishing benign from malignant nodules remains a critical challenge. Emerging evidence suggests that recognizing cancer-associated immune signatures represents a powerful approach for early-stage cancer detection. This study explored the clinical utility of T-cell receptor (TCR) repertoire analysis in IPN evaluation. By conducting large-scale TCR sequencing (6,059 blood and 988 tumor samples), we established LungTCR (https://www.lungtcr.com/), a comprehensive TCR repertoire database, and proposed a method for the quantitative assessment of tumor-related immune responses. LungTCR was leveraged to develop TCRnodseek plus, a diagnostic model integrating clinical data, CT imaging, and TCR features. A multicenter prospective study (ChiCTR2200055761) involving 1,107 patients with IPN validated the superior diagnostic performance of TCRnodseek plus over existing approaches. Mechanistic analyses revealed that the identified lung cancer–related TCR clones are enriched in non–small cell lung cancer and are predominantly present in malignant nodules and tumor tissues. This study provides a robust TCR database and an advanced diagnostic model, offering a framework for precise IPN differentiation.Significance:Construction of the largest TCR database of lung nodules enabled identification of lung cancer–specific TCR sequences and development of an advanced machine learning model to distinguish benign from malignant pulmonary nodules.This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Indeterminate pulmonary nodules (IPN) are increasingly detected due to increasing health awareness and widespread lung cancer screening, yet distinguishing benign from malignant nodules remains a critical challenge. Emerging evidence suggests that recognizing cancer-associated immune signatures represents a powerful approach for early-stage cancer detection. This study explored the clinical utility of T-cell receptor (TCR) repertoire analysis in IPN evaluation. By conducting large-scale TCR sequencing (6,059 blood and 988 tumor samples), we established LungTCR (https://www.lungtcr.com/), a comprehensive TCR repertoire database, and proposed a method for the quantitative assessment of tumor-related immune responses. LungTCR was leveraged to develop TCRnodseek plus, a diagnostic model integrating clinical data, CT imaging, and TCR features. A multicenter prospective study (ChiCTR2200055761) involving 1,107 patients with IPN validated the superior diagnostic performance of TCRnodseek plus over existing approaches. Mechanistic analyses revealed that the identified lung cancer–related TCR clones are enriched in non–small cell lung cancer and are predominantly present in malignant nodules and tumor tissues. This study provides a robust TCR database and an advanced diagnostic model, offering a framework for precise IPN differentiation.Significance:Construction of the largest TCR database of lung nodules enabled identification of lung cancer–specific TCR sequences and development of an advanced machine learning model to distinguish benign from malignant pulmonary nodules.This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Evaluation and external validation of lung cancer-enriched TCR sequences
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Evaluation and external validation of lung cancer-enriched TCR sequences
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Clinical and TCR characteristics for LungTCR database
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Clinical and TCR characteristics for LungTCR database
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
TCR profiling of blood samples from patients with indeterminate pulmonary nodules
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
TCR profiling of blood samples from patients with indeterminate pulmonary nodules
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Biology and Disease Annotation of Enriched CDR3-beta aaSeqs
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Biology and Disease Annotation of Enriched CDR3-beta aaSeqs
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Modified TCR library methodological schematic overview and experimental validation for PCR amplification bias
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Modified TCR library methodological schematic overview and experimental validation for PCR amplification bias
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Feature selection and model construction
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Feature selection and model construction
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Clinical and TCR characteristics for patients with indeterminate pulmonary nodules
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules
Clinical and TCR characteristics for patients with indeterminate pulmonary nodules